Substituted tricyclic compounds as FGFR inhibitors
US11053246B2 · kind B2 · utility
18Cited by
63References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 7, 2020 |
| Grant date | Jul 6, 2021 |
| Priority date | — |
| Expiry date | Apr 7, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D498/22
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.